Recent advances in ytterbium-based contrast agents for in vivo X-ray computed tomography imaging: Promises and prospects

Contrast Media and Molecular Imaging

Volumn 9, Issue 1, 2014, Pages 26-36

  Liu, Yanlan ^a,b   Liu, Jianhua ^c   Ai, Kelong ^a   Yuan, Qinghai ^c   Lu, Lehui ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Chelating complex; Contrast agents; Nanoparticles; PEG; X ray computed tomography; Ytterbium

Indexed keywords

BISMUTH; CONTRAST MEDIUM; GOLD; IRIDIUM; NANOPARTICLE; POLYETHYLENE; TANTALUM; YTTERBIUM;

ANGIOGRAPHY; ARTICLE; CIRCULATION TIME; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; MULTIMODAL IMAGING; NONHUMAN; PRIORITY JOURNAL; ROENTGEN SPECTROSCOPY; X RAY;

CHELATING COMPLEX; CONTRAST AGENTS; NANOPARTICLES; PEG; X-RAY COMPUTED TOMOGRAPHY; YTTERBIUM;

CONTRAST MEDIA; HUMANS; NANOPARTICLES; TOMOGRAPHY, X-RAY COMPUTED; YTTERBIUM;

EID: 84893082226     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1537     Document Type: Article

References (53)

1. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008; 108: 2064-2110.
2. Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging. Nanoscale 2011; 3: 3007-3026.
3. Ntziachristos V. Going deeper than microscopy: the optical imaging frontier in biology. Nat Meth 2010; 7(8): 603-614.
4. Kircher MF, Willmann JK. Molecular body imaging: MR imaging, CT, and US. Part I. Principles. Radiology 2012; 263: 633-643.
5. Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small 2007; 3: 1840-1854.
6. Xing Z, Wang J, Ke H, Zhao B, Yue X, Dai Z, Liu J. The fabrication of novel nanobubble ultrasound contrast agent for potential tumor imaging. Nanotechnology 2010; 21: 145607 .
7. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006; 35: 512-523.
8. Liu YL, Ai KL, Yuan QH, Lu LH. Fluorescence-enhanced gadolinium-doped zinc oxide quantum dots for magnetic resonance and fluorescence imaging. Biomaterials 2011; 32: 1185-1192.
9. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99: 2293-2352.
10. Kalender WA. X-ray computed tomography. Phys Med Biol 2006; 51: R29-43.
11. Liu YL, Ai KL, Lu LH. Nanoparticulate X-ray computed tomography contrast agents: from design validation to in vivo applications. Acc Chem Res 2012; 45: 1807-1827.
12. Roentgen WC. On a new kind of rays. Sitzungsber Phys-Med Ges Wurzburg 1895; 137: S132-1141.
13. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445.
14. DeKrafft KE, Xie Z, Cao G, Tran S, Ma L, Zhou OZ, Lin WB. Iodinated nanoscale coordination polymers as potential contrast agents for computed tomography. Angew Chem Int Ed 2009; 48: 9901-9904.
15. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007; 13: 636-641.
16. Yu SB, Watson AD. Metal-based X-ray contrast media. Chem Rev 1999; 99: 2353-2377.
17. Pan D, Roessl E, Schlomka JP, Caruthers SD, Senpan A, Scott MJ, Allen JS, Zhang H, Hu G, Gaffney PJ, Choi ET, Rasche V, Wickline SA, Proksa R, Lanza GM. Computed tomography in color: nanoK-enhanced spectral CT molecular imaging. Angew Chem Int Ed 2010; 49: 9635-9639.
18. Cheung ENM, Alvares RDA, Oakden W, Chaudhary R, Hill ML, Pichaandi J, Mo GCH, Yip C, Macdonald PM, Stanisz GJ, van Veggel FCJM, Prosser RS. Polymer-stabilized lanthanide fluoride nanoparticle aggregates as contrast agents for magnetic resonance imaging and computed tomography. Chem Mater 2010; 22: 4728-4739.
19. Haller C, Hizoh I. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol 2004; 39: 149-154.
20. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Original investigations. Invest Radiol 2002; 37: 428-434.
21. Krause W Delivery of diagnostic agents in computed tomography. Adv Drug Delivery Rev 1999; 37: 159-173.
22. Eck W, Nicholson AI, Zentgraf H, Semmler W, Bartling S. Anti-CD4-targeted gold nanoparticles induce specific contrast enhancement of peripheral lymph nodes in X-ray computed tomography of live mice. Nano Lett 2010; 10: 2318-2322.
23. Xu CJ, Tung GA, Sun SH. Size and concentration effect of gold nanoparticles on X-ray attenuation as measured on computed tomography. Chem Mater 2008; 20: 4167-4169.
24. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle. bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010; 4: 3689-3696.
25. Kattumuri V, Katti K, Bhaskaran S, Boote EJ, Casteel SW, Fent GM, Robertson DJ, Chandrasekhar M, Kannan R, Katti KV. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: in vivo pharmacokinetics and X-ray-contrast-imaging studies. Small 2007; 3: 333-341.
26. Rabin O, Perez JM, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006; 5: 118-122.
27. Pan D, Williams TA, Senpan A, Allen JS, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J Am Chem Soc 2009; 131: 15522-15527.
28. 3 nanodots as a contrast agent for in vivo X-ray computed tomography imaging. Adv Mater 2011; 23: 4886-4891.
29. Chou SW, Shau YH, Wu PC, Yang YS, Shieh DB, Chen CC. In vitro and in vivo studies of FePt nanoparticles for dual modal CT/MRI molecular imaging. J Am Chem Soc 2010; 132: 13270-13278.
30. Oh MH, Lee N, Kim H, Park SP, Piao Y, Lee J, Jun SW, Moon WK, Choi SH, Hyeon T. Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided Sentinel lymph node mapping. J Am Chem Soc 2011; 133: 5508-5515.
31. Sun IC, Eun DK, Na JH, Lee S, Kim IJ, Youn IC, Ko CY, Kim HS, Lim D, Choi K, Messersmith PB, Park TG, Kim SY, Kwon IC, Kim K, Ahn CH. Heparin-coated gold nanoparticles for liver-specific CT imaging. Chem Eur J 2009; 15: 13341-13347.
32. Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, Gianneschi NC, Ruoslahti E, Stupack D, Sailor MJ. X-Ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Ed 2011; 50: 12308-12311.
33. Xiong LQ, Yang TS, Yang Y, Xu CJ, Li FY. Long-term in vivo biodistribution imaging and toxicity of polyacrylic acid-coated upconversion nanophosphors. Biomaterials 2010; 31: 7078-7085.
34. Emsley J. The Elements. Oxford University Press: New York, 1989.
35. Li ZQ, Zhang Y, Jiang S. Multicolor core/shell-structured upconversion fluorescent nanoparticles. Adv Mater 2009; 20: 4765-4769.
36. Unger E, Gutierrez F. Ytterbium-DTPA a potential intravascular contrast agent. Invest Radiol 1986; 21: 802-807.
37. Zwicker C, Langer M, Langer R, Keske U. Comparison of iodinated and noniodinated contrast media in computed tomography. Invest Radiol 1991; 26: S162-164.
38. Zwicker C, Langer M, Urich V, Felix R. Kontrastgebung von Jod, Gadolinium und ytterbium in der CT. Fortschr Rontgenstr 1993; 158: 255-259.
39. Laniado M, Kopp AF. Liver-specific contrast media: a magic bullet or a weapon for dedicated targets. Radiology 1997; 205: 319-322.
40. Schmitz SA, Wagner S, Schuhmann-Giampieri G, Krause W, Bollow M, Wolf KJ. Gd-EOB-DTPA and Yb-EOB-DTPA: two prototypic contrast media for CT detection of liver lesions in dogs. Radiology 1997; 205: 361-366.
41. Krause W, Handreke K, Schuhmann-Giampieri G, Rupp K. Efficacy of the iodine-free computed tomography liver contrast agent, Dy-EOB-DTPA, in comparison with a conventional iodinated agent in normal and in tumor-bearing rabbits. Invest Radiol 2001; 37: 241-247.
42. Bardhan R, Lal S, Joshi A, Halas NJ. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res 2011; 44: 893-902.
43. Liu YL, Ai KL, Liu JH, Yuan QH, He YY, Lu LH. A high-performance ytterbium-based nanoparticulate contrast agent for in vivo X-ray computed tomography imaging. Angew Chem Int Ed 2012; 51: 1437-1442.
44. 3 up-conversion nanoparticle as an in vivo X-ray CT imaging contrast agent. Biomaterials 2012; 33: 6748-6757.
45. Bjørnerud A, Johansson L. The utility of superparamagnetic contrast agents in MRI: theoretical consideration and applications in the cardiovascular system. NMR Biomed 2004; 17: 465-477.
46. 5 nanoparticles: novel binary contrast agent for high-resolution in vivo X-ray computed tomography angiography. Adv Healthcare Mater 2012; 1: 461-466.
47. Kelly JL, Thickman D, Abramson SD, Chen PR, Smazal SF, Fleishman MJ, Lingam SC. Original research: coronary CT angiography findings in patients without coronary calcification. AJR Am J Roentgenol 2008; 191: 50-55.
48. Pham PH. Computed tomography calcium quantification as a measure of atherosclerotic plaque morphology and stability. Invest Radiol 2006; 41: 674-680.
49. Roessl E, Brendel B, Engel KJ, Schlomka JP, Thran A, Proksa R. Sensitivity of photon-counting based K-edge imaging in X-ray computed tomography. IEEE Trans Med Imag 2011; 30: 1678-1690.
50. Pan D, Schirra CO, Senpan A, Schmieder AH, Stacy AJ, Roessl E, Thran A, Wickline SA, Proska R, Lanza GM. An early investigation of ytterbium nanocolloids for selective and quantitative 'multicolor' spectral CT imaging. ACS Nano 2012; 6: 3364-3370.
51. 3+ nanoprobe for CT and NIR-to-NIR fluorescent bimodal imaging. Biomaterials 2012; 33: 5384-5393.
52. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev 2012; 112: 5818-5878.
53. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, Hulsbergen van de Kaa C, Rosette J, Weissleder R, Engl N. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. J Med 2003; 348: 2491-2499.